3针6万元“神药”翻车以后，百亿抗衰市场如何重生？

Core Viewpoint - The article discusses the recent exposure of exosome products as unregulated and overpriced, highlighting the need for industry regulation and consumer protection in the rapidly growing exosome market [2][6][10]. Industry Overview - Exosomes, small vesicles secreted by cells, are marketed in the beauty and medical fields as anti-aging and health-regulating products, despite being poorly regulated and often lacking clinical evidence [2][4][5]. - The exosome market in China is projected to reach approximately $320 million (about 2.2 billion RMB) in 2024, with an expected growth to over $1.5 billion (about 10.3 billion RMB) by 2030, reflecting a compound annual growth rate of about 25% [5]. Regulatory Challenges - The industry faces significant regulatory challenges, with many companies lacking transparency and clinical trial evidence, leading to misleading marketing practices [5][12]. - Recent government actions, including the "818 Document," aim to establish stricter regulations for biomedical research and clinical applications, emphasizing the need for compliance among companies [12][13]. Market Dynamics - The exposure of fraudulent exosome products is seen as a necessary "clean-up" for the industry, potentially leading to a more regulated and trustworthy market environment [7][10]. - Despite the negative publicity, the exposure has raised awareness of exosomes, which could lead to a more informed consumer base and better industry practices in the long run [14][18]. Investment Landscape - Investment interest in exosome-related companies has shifted from rapid commercialization to a focus on long-term medical applications and overcoming industrial challenges [18][19]. - The complexity of exosome production and quality control presents significant hurdles for companies aiming to establish a reliable market presence [19].